Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
Phase 1/2 study with our HDAC inhibitor mocetinostat in combination with MedImmune’s PD-L1 inhibitor MEDI4736 in patients with Advanced Solid Tumors and NSCLC
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.